WO2004023973A3 - Molecules for diagnostics and therapeutics - Google Patents

Molecules for diagnostics and therapeutics Download PDF

Info

Publication number
WO2004023973A3
WO2004023973A3 PCT/US2003/028227 US0328227W WO2004023973A3 WO 2004023973 A3 WO2004023973 A3 WO 2004023973A3 US 0328227 W US0328227 W US 0328227W WO 2004023973 A3 WO2004023973 A3 WO 2004023973A3
Authority
WO
WIPO (PCT)
Prior art keywords
dithp
provides
therapeutics
diagnostics
diagnostic assays
Prior art date
Application number
PCT/US2003/028227
Other languages
French (fr)
Other versions
WO2004023973A2 (en
Inventor
Jeanette P Schmidt
Rachel J Wright
Christopher M Bruns
Mirjana M Marjanovic
Fan Shen
Toinette A Harthshorne
Martin T Suchorolski
Christina M Altus
Steven J Pitts
Linda V Elder
Original Assignee
Incyte Corp
Jeanette P Schmidt
Rachel J Wright
Christopher M Bruns
Mirjana M Marjanovic
Fan Shen
Toinette A Harthshorne
Martin T Suchorolski
Christina M Altus
Steven J Pitts
Linda V Elder
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Incyte Corp, Jeanette P Schmidt, Rachel J Wright, Christopher M Bruns, Mirjana M Marjanovic, Fan Shen, Toinette A Harthshorne, Martin T Suchorolski, Christina M Altus, Steven J Pitts, Linda V Elder filed Critical Incyte Corp
Priority to AU2003289716A priority Critical patent/AU2003289716A1/en
Publication of WO2004023973A2 publication Critical patent/WO2004023973A2/en
Publication of WO2004023973A3 publication Critical patent/WO2004023973A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/136—Screening for pharmacological compounds
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/142—Toxicological screening, e.g. expression profiles which identify toxicity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers

Abstract

The present invention provides purified human polynucleotides for diagnostics and therapeutics (dithp). Also encompassed are the polypeptides (DITHP) encoded by dithp. The invention also provides for the use of dithp, or complements, oligonucleotides, or fragments thereof in diagnostic assays. The invention further provides for vectors and host cells containing ditph for the expression of DITHP. The invention additionally provides for the use of isolated and purified DITHP to induce antibodies and to screen libraries of compounds and the use of anti-DITHP antibodies in diagnostic assays. Also provided are microarrays containing dithp and methods of use.
PCT/US2003/028227 2002-09-12 2003-09-12 Molecules for diagnostics and therapeutics WO2004023973A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2003289716A AU2003289716A1 (en) 2002-09-12 2003-09-12 Molecules for diagnostics and therapeutics

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US41025902P 2002-09-12 2002-09-12
US41026002P 2002-09-12 2002-09-12
US60/410,259 2002-09-12
US60/410,260 2002-09-12

Publications (2)

Publication Number Publication Date
WO2004023973A2 WO2004023973A2 (en) 2004-03-25
WO2004023973A3 true WO2004023973A3 (en) 2004-09-23

Family

ID=31997928

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2003/028227 WO2004023973A2 (en) 2002-09-12 2003-09-12 Molecules for diagnostics and therapeutics

Country Status (2)

Country Link
AU (1) AU2003289716A1 (en)
WO (1) WO2004023973A2 (en)

Cited By (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8168180B2 (en) 2002-11-27 2012-05-01 Technion Research & Development Foundation Ltd. Methods and compositions for modulating angiogenesis
US8461303B2 (en) 2007-08-02 2013-06-11 Gilead Biologics, Inc. LOX and LOXL2 inhibitors and uses thereof
US8927700B2 (en) 2009-08-21 2015-01-06 Gilead Biologics, Inc. Catalytic domains from lysyl oxidase and LOXL2
US9107935B2 (en) 2009-01-06 2015-08-18 Gilead Biologics, Inc. Chemotherapeutic methods and compositions
US9127268B2 (en) 2009-12-11 2015-09-08 Atyr Pharma, Inc. Aminoacyl tRNA synthetases for modulating inflammation
CN105111311A (en) * 2005-12-20 2015-12-02 Sbi生物技术有限公司 Anti-ILT7-antibody
US9273302B2 (en) 2012-02-16 2016-03-01 Atyr Pharma, Inc. Histidyl-tRNA synthetases for treating autoimmune and inflammatory diseases
US9284609B2 (en) 2005-09-12 2016-03-15 The Brigham And Women's Hospital, Inc. Recurrent gene fusions in prostate cancer
US9303291B2 (en) 2007-07-06 2016-04-05 The Regents Of The University Of Michigan MIPOL1-ETV1 gene rearrangements
US9340780B2 (en) 2010-05-03 2016-05-17 Atyr Pharma, Inc. Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of seryl-tRNA synthetases
US9422539B2 (en) 2010-07-12 2016-08-23 Atyr Pharma, Inc. Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of histidyl-tRNA synthetases
US9428743B2 (en) 2010-08-25 2016-08-30 Atyr Pharma, Inc. Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of tyrosyl-trna synthetases
US9587235B2 (en) 2013-03-15 2017-03-07 Atyr Pharma, Inc. Histidyl-tRNA synthetase-Fc conjugates

Families Citing this family (78)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2002364939A1 (en) * 2001-10-22 2003-07-09 Board Of Regents, The University Of Texas System Sperm-specific cation channel, catsper2, and uses therefor
WO2004016733A2 (en) 2002-08-16 2004-02-26 Agensys, Inc. Nucleic acid and corresponding protein entitled 251p5g2 useful in treatment and detection of cancer
EP1581641A4 (en) * 2002-12-06 2006-11-15 Diadexus Inc Compositions, splice variants and methods relating to ovarian specific genes and proteins
US8871709B2 (en) * 2003-02-05 2014-10-28 Queensland University of Technolgy Synthetic chimeric proteins comprising epidermal growth factor and vitronectin
EP1615991A4 (en) 2003-04-03 2007-12-19 Bristol Myers Squibb Co Polynucleotide encoding a novel human p2x7 splice variant, hbmyp2x7v
WO2004094623A2 (en) * 2003-04-04 2004-11-04 Incyte Corporation Cell adhesion and extracellular matrix proteins
US20060247421A1 (en) * 2003-05-14 2006-11-02 Ko Fujimori Liver x receptor alpha splicing mutant protein, gene thereof and utilization of the same
CN1894409A (en) 2003-08-18 2007-01-10 惠氏公司 Human LXR alpha variants
US20070238655A1 (en) * 2003-11-12 2007-10-11 The Trustees Of The University Of Pennsylvania Methods of Using Gelsolin to Treat or Prevent Bacterial Sepsis
US9408891B2 (en) 2003-11-12 2016-08-09 The Trustees Of The University Of Pennsylvania Methods of using gelsolin to treat or prevent bacterial sepsis
ATE510020T1 (en) * 2003-12-24 2011-06-15 G2 Inflammation Pty Ltd TRANSGENIC NON-HUMAN MAMMAL WITH A POLYNUCLEOTIDE CODING FOR HUMAN-C5AR OR HUMANIZED C5AR
WO2005076012A2 (en) * 2004-01-30 2005-08-18 Five Prime Therapeutics, Inc. Novel splice variants and methods of use thereof
US20050186577A1 (en) 2004-02-20 2005-08-25 Yixin Wang Breast cancer prognostics
US8124730B1 (en) 2004-04-02 2012-02-28 Bristol-Myers Squibb Company Polynucleotide encoding a novel human P2X7 splice variant, HBMYP2X7v
EP1586587A1 (en) * 2004-04-16 2005-10-19 Exonhit Therapeutics SA Compositions and methods for detecting angiogenesis
EP1755661B1 (en) 2004-05-12 2014-03-12 The Brigham And Women's Hospital, Inc. Gelsolin for use in treating infections
WO2006008008A2 (en) * 2004-07-23 2006-01-26 Bayer Healthcare Ag Diagnostics and therapeutics for diseases associated with hepatocyte nuclear factor 4, alpha (hnf4a)
US20090004193A1 (en) * 2004-07-23 2009-01-01 Bayer Healthcare Ag Diagnostics and Therapeutics for Diseases Associated With Vasoactive Intestinal Peptide Receptor 1 (Vpac1)
DK1802749T3 (en) * 2004-10-21 2012-11-26 Mayo Foundation KASPP (LRRK2) gene, its preparation and use for the detection and treatment of neurodegenerative disorders
CA2590751A1 (en) 2004-12-13 2006-06-22 Roy Rabindranauth Sooknanan Polynucleotides and polypeptide sequences involved in the process of bone remodeling
KR100664587B1 (en) * 2004-12-22 2007-01-04 김현기 Human cancer suppressor gene protein encoded therein expression vector containing same and cell transformed by said vector
US20090133135A1 (en) 2005-06-01 2009-05-21 Evotec Neurosciences Gmbh Diagnostic and Therapeutic Target SLC39A11 Proteins for Neurodegenerative Diseases
EP1739092A1 (en) * 2005-06-28 2007-01-03 I.N.S.E.R.M. Institut National de la Sante et de la Recherche Medicale Peptidic antagonists of class III semaphorins/neuropilins complexes
US9957569B2 (en) 2005-09-12 2018-05-01 The Regents Of The University Of Michigan Recurrent gene fusions in prostate cancer
AU2012244391B2 (en) * 2005-12-20 2014-09-11 Sbi Biotech Co., Ltd. Anti-ILT7 antibody
AU2014265023A1 (en) * 2005-12-20 2014-12-04 Sbi Biotech Co, Ltd. Anti-ILT7 Antibody
US8383799B2 (en) 2006-01-20 2013-02-26 Cell Signaling Technology, Inc. Translocation and mutant ROS kinase in human non-small cell lung carcinoma
EP3360965A1 (en) * 2006-01-20 2018-08-15 Cell Signaling Technology, Inc. Translocation and mutant ros kinase in human non-small cell lung carcinoma
US20070192885A1 (en) * 2006-01-26 2007-08-16 Daniel Chelsky TAT-039 and methods of assessing and treating cancer
WO2007089783A2 (en) * 2006-01-30 2007-08-09 Caprion Pharmaceuticals, Inc. Tat-044 and methods of assessing and treating cancer
WO2007089793A2 (en) * 2006-01-31 2007-08-09 Caprion Pharmaceuticals, Inc. Tat-041 and methods of assessing and treating cancer
PL2001496T3 (en) 2006-03-15 2017-10-31 Brigham & Womens Hospital Inc Use of gelsolin to diagnose and treat inflammatory diseases
US8440622B2 (en) 2006-03-15 2013-05-14 The Brigham And Women's Hospital, Inc. Use of gelsolin to treat multiple sclerosis and to diagnose neurologic disease (stossel)
US7452985B2 (en) 2006-08-17 2008-11-18 Visgeneer, Inc. Human Ron-related gene variant associated with cancers
EP1892248A1 (en) * 2006-08-21 2008-02-27 Eidgenössische Technische Hochschule Zürich Specific and high affinity binding proteins comprising modified SH3 domains of FYN kinase
US9689879B2 (en) 2006-08-21 2017-06-27 Eidgenoessische Technische Hochschule Zurich Specific and high affinity binding proteins comprising modified SH3 domains of Fyn kinase
US9513296B2 (en) 2006-08-21 2016-12-06 Eidgenoessische Technische Hochschule Zurich Specific and high affinity binding proteins comprising modified SH3 domains of Fyn kinase
WO2008042814A2 (en) * 2006-09-29 2008-04-10 California Institute Of Technology Mart-1 t cell receptors
WO2008066691A2 (en) 2006-11-08 2008-06-05 Macrogenics West, Inc. Tes7 and antibodies that bind thereto
US8106037B2 (en) 2007-08-03 2012-01-31 The Brigham And Women's Hospital, Inc. Identification and treatment of estrogen responsive prostate tumors
JP5580205B2 (en) 2007-11-19 2014-08-27 セレラ コーポレーション Lung cancer markers and their use
EP2242770A2 (en) * 2008-01-07 2010-10-27 Patrys Limited Barb4 target which comprises tata-binding protein-associated factor 15, antibody designated barb4, barb4 related antibodies, and methods of making and using same
US9575072B2 (en) 2008-01-25 2017-02-21 The Brigham And Women's Hospital, Inc. Diagnostic and therapeutic uses of gelsolin in renal failure
WO2009131605A2 (en) * 2008-01-28 2009-10-29 Thomas Jefferson University Fusion partner cell line for preparation of hybrid cells expressing human antibodies
AU2013202419B2 (en) * 2008-07-16 2014-11-27 Institute For Research In Biomedicine Human cytomegalovirus neutralizing antibodies and uses thereof
WO2010008051A1 (en) 2008-07-16 2010-01-21 株式会社医学生物学研究所 Anti-human clcp1 antibody and use thereof
WO2010033294A1 (en) 2008-09-22 2010-03-25 Cedars-Sinai Medical Center Short-form human md-2 as a negative regulator of toll-like receptor 4 signaling
US9512196B2 (en) 2008-09-22 2016-12-06 Cedars-Sinai Medical Center Short-form human MD-2 as a negative regulator of toll-like receptor 4 signaling
EP3913367A1 (en) * 2008-12-30 2021-11-24 Children's Medical Center Corporation Method of predicting acute appendicitis
WO2010107825A2 (en) 2009-03-16 2010-09-23 Pangu Biopharma Limited Compositions and methods comprising histidyl-trna synthetase splice variants having non-canonical biological activities
JP4495776B1 (en) * 2009-07-30 2010-07-07 日本製薬株式会社 Fusion protein
EP2478120B1 (en) 2009-09-17 2015-09-02 The Regents Of The University Of Michigan Recurrent gene fusions in prostate cancer
CN103755809B (en) 2009-11-30 2016-06-01 霍夫曼-拉罗奇有限公司 The antibody of the tumour of SLC34A2 (TAT211=SEQID2) is expressed in treatment and diagnosis
UA109888C2 (en) 2009-12-07 2015-10-26 ANTIBODY OR ANTIBODILITY ANTIBODY OR ITS BINDING TO THE β-CLOTE, FGF RECEPTORS AND THEIR COMPLEXES
US8828395B2 (en) 2009-12-11 2014-09-09 Atyr Pharma, Inc. Antibodies that bind tyrosyl-tRNA synthetases
CN103154034B (en) 2010-04-13 2016-06-08 塞尔德克斯医疗公司 In conjunction with antibody of people CD27 and uses thereof
WO2012042038A2 (en) * 2010-09-30 2012-04-05 Institut National De La Sante Et De La Recherche Medicale (Inserm) Chimeric peptides including a penetrating peptide and a binding domain of pp2a catalytic subunit to caspase-9
US8945556B2 (en) 2010-11-19 2015-02-03 The Regents Of The University Of Michigan RAF gene fusions
WO2013022982A2 (en) 2011-08-09 2013-02-14 Atyr Pharma, Inc. Pegylated tyrosyl-trna synthetase polypeptides
WO2013063010A1 (en) * 2011-10-26 2013-05-02 Nuclea Biotechnologies, Inc. Usp2a peptides and antibodies
WO2013164970A1 (en) * 2012-05-01 2013-11-07 富士フイルム株式会社 Method for incubating pluripotent stem cells and polypeptide to be used therefor
CN105007939B (en) * 2012-10-05 2018-10-19 卡德门企业有限公司 People's anti-VEGFR-2/KDR antibody
WO2014153195A1 (en) 2013-03-14 2014-09-25 Bayer Healthcare Llc Monoclonal antibodies against antithrombin beta complexed with heparin
US11519916B2 (en) 2015-06-08 2022-12-06 Arquer Diagnostics Limited Methods for analysing a urine sample
WO2016198835A1 (en) 2015-06-08 2016-12-15 Arquer Diagnostics Limited Methods and kits
EP3331356A4 (en) * 2015-08-04 2019-04-10 New York University Progranulin (pgrn) fragments and derivatives for treatment or alleviation of lysosomal storage diseases
KR102632796B1 (en) 2016-03-10 2024-02-02 비엘라 바이오, 인크. Ilt7 binding molecules and methods of using the same
KR102473964B1 (en) * 2016-04-08 2022-12-06 이뮤노코어 리미티드 T cell receptor
AU2018256435A1 (en) 2017-04-20 2019-11-07 Atyr Pharma, Inc. Compositions and methods for treating lung inflammation
CN110612116A (en) 2017-05-08 2019-12-24 磨石肿瘤生物技术公司 Novel alphavirus antigen vector
CA3066569A1 (en) 2017-06-07 2018-12-13 Regeneron Pharmaceuticals, Inc. Compositions and methods for internalizing enzymes
KR20200036912A (en) * 2017-07-31 2020-04-07 리플렉션 바이오테크놀러지스 리미티드 Cell model and therapy for ophthalmic diseases
MX2020007077A (en) 2018-01-04 2020-10-28 Iconic Therapeutics Inc Anti-tissue factor antibodies, antibody-drug conjugates, and related methods.
GB201803010D0 (en) 2018-02-26 2018-04-11 Royal Holloway & Bedford New College Neurodegenerative disorders
EP3781265A2 (en) 2018-04-17 2021-02-24 Celldex Therapeutics, Inc. Anti-cd27 and anti-pd-l1 antibodies and bispecific constructs
BR122024002387A2 (en) 2019-05-30 2024-03-12 Gritstone Bio, Inc. ADENOVIRUS VECTORS, PHARMACEUTICAL COMPOSITION, ISOLATED NUCLEOTIDE SEQUENCE, ISOLATED CELL, VECTOR, KIT, USES OF A VECTOR, METHOD FOR MAKING THE VECTOR, METHODS FOR PRODUCING A VIRUS AND VIRAL VECTOR
CN111859913B (en) * 2020-06-12 2024-04-12 北京百度网讯科技有限公司 Processing method and device of wind control characteristic factors, electronic equipment and storage medium
AU2021320896A1 (en) 2020-08-06 2023-03-23 Gritstone Bio, Inc. Multiepitope vaccine cassettes

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001053531A2 (en) * 2000-01-18 2001-07-26 Pharmacia Corporation Osteoarthritis tissue derived nucleic acids, polypeptides, vectors, and cells

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001053531A2 (en) * 2000-01-18 2001-07-26 Pharmacia Corporation Osteoarthritis tissue derived nucleic acids, polypeptides, vectors, and cells

Cited By (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8168180B2 (en) 2002-11-27 2012-05-01 Technion Research & Development Foundation Ltd. Methods and compositions for modulating angiogenesis
US9284609B2 (en) 2005-09-12 2016-03-15 The Brigham And Women's Hospital, Inc. Recurrent gene fusions in prostate cancer
CN105111311B (en) * 2005-12-20 2019-10-18 Sbi生物技术有限公司 Anti-ilt 7 antibody
CN105111311A (en) * 2005-12-20 2015-12-02 Sbi生物技术有限公司 Anti-ILT7-antibody
US9303291B2 (en) 2007-07-06 2016-04-05 The Regents Of The University Of Michigan MIPOL1-ETV1 gene rearrangements
US8461303B2 (en) 2007-08-02 2013-06-11 Gilead Biologics, Inc. LOX and LOXL2 inhibitors and uses thereof
US8679485B2 (en) 2007-08-02 2014-03-25 Gilead Biologics, Inc. Methods and compositions for treatment and diagnosis of fibrosis, tumor invasion, angiogenesis, and metastasis
US9176139B2 (en) 2007-08-02 2015-11-03 Gilead Biologics, Inc. LOX and LOXL2 inhibitors and uses thereof
US9107935B2 (en) 2009-01-06 2015-08-18 Gilead Biologics, Inc. Chemotherapeutic methods and compositions
US9289447B2 (en) 2009-01-06 2016-03-22 Gilead Biologics, Inc. Chemotherapeutic methods and compositions
US8927700B2 (en) 2009-08-21 2015-01-06 Gilead Biologics, Inc. Catalytic domains from lysyl oxidase and LOXL2
US9328340B2 (en) 2009-12-11 2016-05-03 Atyr Pharma, Inc. Amino acyl tRNA synthetases for modulating inflammation
US9540628B2 (en) 2009-12-11 2017-01-10 Atyr Pharma, Inc. Aminoacyl tRNA synthetases for modulating inflammation
US9127268B2 (en) 2009-12-11 2015-09-08 Atyr Pharma, Inc. Aminoacyl tRNA synthetases for modulating inflammation
US9340780B2 (en) 2010-05-03 2016-05-17 Atyr Pharma, Inc. Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of seryl-tRNA synthetases
US9422539B2 (en) 2010-07-12 2016-08-23 Atyr Pharma, Inc. Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of histidyl-tRNA synthetases
US9428743B2 (en) 2010-08-25 2016-08-30 Atyr Pharma, Inc. Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of tyrosyl-trna synthetases
US9273302B2 (en) 2012-02-16 2016-03-01 Atyr Pharma, Inc. Histidyl-tRNA synthetases for treating autoimmune and inflammatory diseases
US9587235B2 (en) 2013-03-15 2017-03-07 Atyr Pharma, Inc. Histidyl-tRNA synthetase-Fc conjugates

Also Published As

Publication number Publication date
WO2004023973A2 (en) 2004-03-25
AU2003289716A8 (en) 2004-04-30
AU2003289716A1 (en) 2004-04-30

Similar Documents

Publication Publication Date Title
WO2004023973A3 (en) Molecules for diagnostics and therapeutics
WO2002097031A3 (en) Molecules for diagnostics and therapeutics
WO2000073509A3 (en) Molecules for diagnostics and therapeutics
WO2002083876A3 (en) Secretory molecules
WO2005056600A3 (en) Monoclonal antibodies that bind or neutralize dengue virus
WO2005069854A3 (en) Methods and materials relating to novel c1q domain-containing polypeptides and polynucleotides
WO2002046228A3 (en) Receptor for b. anthracis toxin
WO2003020894A3 (en) Insulin related transcription factor and uses thereof
WO2003062376A3 (en) Molecules for diagnostics and therapeutics
WO2002040715A8 (en) Molecules for disease detection and treatment
WO2002020756A3 (en) Secretory molecules
WO2003062385A3 (en) Secretory molecules
WO2001062927A3 (en) Polypeptides and corresponding polynucleotides for diagnostics and therapeutics
WO2001062922A3 (en) Polypeptides and corresponding molecules for disease detection and treatment
WO2002020754A3 (en) Molecules for diagnostics and therapeutics
WO2004066933A3 (en) Compositions and methods for treating cancer using igsf9 and liv-1
WO2002055738A3 (en) Molecules for disease detection and treatment
WO2001062918A3 (en) Secretory polypeptides and corresponding polynucleotides
WO2002079473A3 (en) Molecules for diagnostics and therapeutics
WO2001021836A3 (en) Molecules for diagnostics and therapeutics
WO2008124170A3 (en) SELECTION OF HUMAN TNFα SPECIFIC ANTIBODIES
WO2003008626A3 (en) Novel human nucleic acids encoding a pantothenate kinase and methods of use
WO2000075298A3 (en) Molecules for disease detection and treatment
WO2002057304A3 (en) Secretory molecules
WO2003027231A3 (en) Polynucleotide encoding adapter protein, pmn29

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SK SL TJ TM TN TR TT TZ UA UG US UZ VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP